Search | OpenScholar

Search results

1963 results found

Sexual dimorphism in the progression of type 2 diabetic kidney disease in T2DN rats

Publication: Journal Article

DR, Spires, O Palygin, V Levchenko, E Isaeva, CA Klemens, S Khedr, O Nikolaienko, et al. 2021. “Sexual Dimorphism in the Progression of Type 2 Diabetic Kidney Disease in T2DN Rats”. Physiological Genomics.

Fever-triggered ventricular arrhythmias in Brugada syndrome and type 2 long-QT syndrome.

Publication: Journal Article

Amin, AS, CA Klemens, AO Verkerk, PG Meregalli, Roodsari Asghari, JM de Bakker, CT January, AA Wilde, and HL Tan. 2010. “Fever-Triggered Ventricular Arrhythmias in Brugada Syndrome and Type 2 Long-QT Syndrome.”. Neth Heart J.

for the P2B Study Group. Double-Blind Study comparing P2B001 (combination of low-doses of extended-release Pramipexole and Rasagiline) to components and to optimised doses of Pramipexole-extended release in early Parkinson’s Disease.

Publication: Journal Article

Hauser, RA, CW Olanow, D Burdick, R Dhall, JA de Marcaida, RA Gil, DL Kreitzman, L Elmer, A McGarry, and K Kieburtz. 2024. “For the P2B Study Group. Double-Blind Study Comparing P2B001 (combination of Low-Doses of Extended-Release Pramipexole and Rasagiline) to Components and to Optimised Doses of Pramipexole-Extended Release in Early Parkinson’s Disease.”. . Mov Disord. 2024 Feb;39(2):350-359. Doi: 10.1002/Mds.29642. Epub 2023 Oct 27. PMID: 37886872.

Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: Considerations for initiation and maintenance.

Publication: Journal Article

Fung, VSC, J Aldred, MP Arroyo, F Bergquist, RA Hauser, M Bouchard, S Bray, et al. 2024. “Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion for the Treatment of Motor Fluctuations in Parkinson’s Disease: Considerations for Initiation and Maintenance.”. . Clin Park Relat Disord. 2024 Feb 10;10:100239. Doi: 10.1016/J.prdoa.2024.100239. ECollection 2024. PMID: 38419617.

OFF-times before, during, and after nighttime sleep periods in Parkinson's disease patients with motor fluctuations and the effects of opicapone: A post hoc analysis of diary data from BIPARK-1 and -2.

Publication: Journal Article

Hauser, RA, A Videnovic, P Soares-da-Silva, GS Liang, K Olson, E Jen, JF Rocha, and O Klepitskaya. 2024. “OFF-Times Before, During, and After Nighttime Sleep Periods in Parkinson’s Disease Patients With Motor Fluctuations and the Effects of Opicapone: A Post Hoc Analysis of Diary Data from BIPARK-1 and -2.”. Parkinsonism Relat Disord. 2024 Jun;123:106971. Doi: 10.1016/J.Parkreldis.2024.106971. Epub 2024 Apr 9.PMID: 38631081 .

The Clinical Development of Levodopa Inhalation Powder. 2023 Mar-Apr 01;46(2):66-78. doi: 10.1097/WNF.0000000000000540. Epub 2023 Jan 29. PMID: 36715241

Publication: Journal Article

Hauser, RA, PA LeWitt, CH Waters, DG Grosset, and B Blank. 2023. “The Clinical Development of Levodopa Inhalation Powder. 2023 Mar-Apr 01;46(2):66-78. Doi: 10.1097/WNF.0000000000000540. Epub 2023 Jan 29. PMID: 36715241”. Clin Neuropharmacol.

Members of the IPMDS Rating Scales Review Committee. Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations. 2023 Jun;38(6):1008-1026. doi: 10.1002/mds.29392. Epub 2023 Apr 20. PMID: 37081740

Publication: Journal Article

Martino, D, V Karnik, R Bhidayasiri, DA Hall, RA Hauser, A Macerollo, TM Pringheim, et al. 2023. “Members of the IPMDS Rating Scales Review Committee. Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations. 2023 Jun;38(6):1008-1026. Doi: 10.1002/Mds.29392. Epub 2023 Apr 20. PMID: 37081740”. Mov Disord.

Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment. Neurol Ther. 2022 Mar;11(1):459-469. doi: 10.1007/s40120-021-00317-5. Epub 2022 Feb 2. PMID: 35107750.

Publication: Journal Article

Hauser, RA, A Favit, LA Hewitt, A Lindsten, S Gomy, S Kymes, and SH Isaacson. 2022. “Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment. Neurol Ther. 2022 Mar;11(1):459-469. Doi: 10.1007/S40120-021-00317-5. Epub 2022 Feb 2. PMID: 35107750.”. Neurol Ther.

P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease. Adv Ther. 2022 May;39(5):1881-1894. doi: 10.1007/s12325-022-02097-2. Epub 2022 Mar 10. PMID: 35267155.

Publication: Journal Article

Hauser, RA, N Giladi, W Poewe, J Brotchie, H Friedman, S Oren, and P Litman. 2022. “P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson’s Disease. Adv Ther. 2022 May;39(5):1881-1894. Doi: 10.1007/S12325-022-02097-2. Epub 2022 Mar 10. PMID: 35267155.”. Adv. Ther.

Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study. 2022 Feb 23;13:773999. doi: 10.3389/fneur.2022.773999. eCollection 2022. PMID: 35280262.

Publication: Journal Article

Hauser, RA, H Barkway, HH Fernandez, SA Factor, J Jimenez-Shahed, N Gross, L Marinelli, et al. 2022. “Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study. 2022 Feb 23;13:773999. Doi: 10.3389/Fneur.2022.773999. ECollection 2022. PMID: 35280262.”. Front Neurol.